Literature DB >> 23222696

Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: a review of the literature.

Suat-Jin Lu1, Gopinath Gnanasegaran, John Buscombe, Shaunak Navalkissoor.   

Abstract

The scintigraphic investigation of neuroendocrine tumours such as carcinoids has depended on standard techniques such as I-metaiodobenzylguanidine and In-pentetreotide imaging. More recently, the use of PET techniques such as Ga-DOTATATE has been advocated. An alternative improved modality is high-quality single photon emission computed tomography/computed tomography (SPECT/CT), which has the advantages of better sensitivity and specificity and has shown improved localization in up to 60% of cases. These advantages are especially true for pancreatic and lymph node lesions. Overall, SPECT/CT can result in a change in clinical management in 25% of patients. Although it is possible to combine SPECT and CT performed at different time points, there is better anatomical localization and improved reporter confidence when SPECT and CT are performed simultaneously.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23222696     DOI: 10.1097/MNM.0b013e32835bd59d

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  9 in total

Review 1.  Molecular imaging agents for SPECT (and SPECT/CT).

Authors:  Gopinath Gnanasegaran; James R Ballinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-07       Impact factor: 9.236

Review 2.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

Authors:  Martijn van Essen; Anders Sundin; Eric P Krenning; Dik J Kwekkeboom
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

Review 3.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

4.  Imaging in neuroendocrine tumors: an update for the clinician.

Authors:  Jessica E Maxwell; James R Howe
Journal:  Int J Endocr Oncol       Date:  2015

Review 5.  Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis.

Authors:  Håkan Geijer; Lars H Breimer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-20       Impact factor: 9.236

6.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

Review 7.  Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).

Authors:  Rima Hajjo; Dima A Sabbah; Sanaa K Bardaweel; Alexander Tropsha
Journal:  Diagnostics (Basel)       Date:  2021-04-21

Review 8.  Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.

Authors:  Andreas Kjaer; Ulrich Knigge
Journal:  Scand J Gastroenterol       Date:  2015-06       Impact factor: 2.423

9.  A novel statistical analysis method to improve the detection of hepatic foci of (111)In-octreotide in SPECT/CT imaging.

Authors:  Tobias Magnander; E Wikberg; J Svensson; P Gjertsson; B Wängberg; M Båth; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2016-01-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.